Other languages Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Market Closed - Nyse Other stock markets 21:00:02 01/05/2024 BST			5-day change	1st Jan Change
8.75 ^USD	-0.11%		+2.22%	+9.10%

05-01	Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	MT
05-01	Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says	04-23
RBC Previews Bausch Health's Q1, Trims Target to US$11	04-23
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	04-12
Bausch wins US appeal to block Alvogen generic of diarrhea drug	04-11
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	04-11
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	04-08
RBC Raises Bausch Health Target to US$12, Maintains Sector Perform, on Upcoming Xifaxan Litigation Ruling	04-05
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults	04-03
Toronto healthcare stocks rise in flat market, Canada Goose slides	03-26
Insider - Milliardäre sammelten Geld für Trumps Sicherheitsleistung	03-26
Billionaires sought to help fund Trump bond in civil fraud case, sources say	03-26
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor	03-06
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma	03-06
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance	02-23
TSX closes at 22-month high powered by tech rally	02-22
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says	02-22
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell	02-22
Bausch Health Reports Q4 2023 Adjusted Earnings of US$406 Million; Revenue of US$2.4 Billion	02-22
Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2024	02-22
Bausch Health Companies Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Other languages

Filters